Elevation Oncology
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Elevation Oncology (Nasdaq: ELEV), based in Boston, was an oncology company developing selective cancer therapies for solid tumors with unmet medical needs. Its remaining pipeline asset was EO-1022, a HER3-targeted antibody-drug conjugate in preclinical development. After activist investor pressure to wind down, the board accepted a buyout from Concentra Biosciences, a Tang Capital vehicle that acquires struggling biotechs.
02 / Elevation Oncology FAILURE REASONS
Failure factors
Updated clinical results for EO-3021 did not meet the company’s efficacy expectations or competitive benefit-risk threshold. It discontinued the program, reduced staff and evaluated strategic options.
03 / EVENT HISTORY
Events in the structured record
- Acquisition
A buyout intended to wind down Elevation Oncology was announced in 2025, following termination of its lead clinical program.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Selective cancer therapies for solid tumors
- 02
Sole asset EO-1022, preclinical
- 03
Activist pressure; board accepts buyout
- 04
Acquired July 2025 for $0.36/share; delisted